JP2025505434A5 - - Google Patents
Info
- Publication number
- JP2025505434A5 JP2025505434A5 JP2024545121A JP2024545121A JP2025505434A5 JP 2025505434 A5 JP2025505434 A5 JP 2025505434A5 JP 2024545121 A JP2024545121 A JP 2024545121A JP 2024545121 A JP2024545121 A JP 2024545121A JP 2025505434 A5 JP2025505434 A5 JP 2025505434A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- cancer
- drugs
- optionally
- prodrug construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22154258 | 2022-01-31 | ||
| EP22154258.2 | 2022-01-31 | ||
| PCT/EP2023/052280 WO2023144412A1 (en) | 2022-01-31 | 2023-01-31 | A biopharmaceutical prodrug platform based on protein conformational change |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025505434A JP2025505434A (ja) | 2025-02-26 |
| JP2025505434A5 true JP2025505434A5 (https=) | 2026-01-29 |
Family
ID=80118874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024545121A Pending JP2025505434A (ja) | 2022-01-31 | 2023-01-31 | タンパク質構造変化に基づくバイオ医薬プロドラッグプラットホーム |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240374745A1 (https=) |
| EP (1) | EP4473007A1 (https=) |
| JP (1) | JP2025505434A (https=) |
| CN (1) | CN118613501A (https=) |
| AU (1) | AU2023211165A1 (https=) |
| CA (1) | CA3243392A1 (https=) |
| WO (1) | WO2023144412A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024261212A1 (en) * | 2023-06-22 | 2024-12-26 | Aarhus Universitet | Multi-specific proteinaceous prodrug constructs |
| WO2025128434A1 (en) * | 2023-12-14 | 2025-06-19 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for the treatment of ven/aza resistant acute myeloid leukemia |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2324864A1 (en) * | 1998-04-01 | 1999-10-07 | Duke University | Immune response modulator alpha-2 macroglobulin complex |
| SG175602A1 (en) * | 2006-07-05 | 2011-11-28 | Catalyst Biosciences Inc | Protease screening methods and proteases identified thereby |
| JP6861152B2 (ja) * | 2014-11-20 | 2021-04-21 | サイトニックス コーポレイション | 治療用変異体アルファ２−マクログロブリン組成物 |
| EP3762406A2 (en) * | 2018-03-09 | 2021-01-13 | Askgene Pharma, Inc. | Cytokine prodrugs |
| AU2019271148B9 (en) * | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| WO2019222282A1 (en) * | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Conditionally activated binding protein comprising a sterically occluded target binding domain |
-
2023
- 2023-01-31 JP JP2024545121A patent/JP2025505434A/ja active Pending
- 2023-01-31 CA CA3243392A patent/CA3243392A1/en active Pending
- 2023-01-31 CN CN202380019053.5A patent/CN118613501A/zh active Pending
- 2023-01-31 AU AU2023211165A patent/AU2023211165A1/en active Pending
- 2023-01-31 EP EP23702149.8A patent/EP4473007A1/en active Pending
- 2023-01-31 WO PCT/EP2023/052280 patent/WO2023144412A1/en not_active Ceased
-
2024
- 2024-07-31 US US18/790,586 patent/US20240374745A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250074967A1 (en) | Immunomodulatory fusion proteins | |
| CA2993891C (en) | Interleukin-15 fusion proteins for tumor targeting therapy | |
| KR101281208B1 (ko) | 피브로넥틴 ｅｄ-ｂ에 대한 항체 ｌ１９ 및 인터루킨１２의 융합 단백질 | |
| JP2025505434A5 (https=) | ||
| ES2327409T3 (es) | Proteinas de fusion fc mejoradas. | |
| JP2021511069A (ja) | 抗体Ｆｃ領域を主鎖として用いた融合タンパク質二量体及びその使用 | |
| JP2020508691A5 (https=) | ||
| CN112534052A (zh) | 全新il-21前药及使用方法 | |
| CN114144193A (zh) | 一种液体制剂及其应用 | |
| JP7702445B2 (ja) | 免疫調節融合タンパク質 | |
| WO2015103928A1 (zh) | Il-15异源二聚体蛋白及其用途 | |
| US20240344025A1 (en) | Synthetic immuno-suppressive cells and methods of use thereof | |
| US20240374745A1 (en) | Biopharmaceutical prodrug platform based on protein conformational change | |
| CN116003571A (zh) | 一种分泌Fc-IL-2m融合蛋白的改良型CAR-T细胞及其应用 | |
| CN110590959B (zh) | 重组犬pd-1融合蛋白及其制备方法与应用 | |
| US20240207404A1 (en) | Bispecific in tandem receptor car and method for modulating the tumoral microenvironment | |
| TW202444743A (zh) | 干擾素α受體的變異體、包括其之融合蛋白及其用途 | |
| AU2024312715A1 (en) | Multi-specific proteinaceous prodrug constructs | |
| Lee | Rational Engineering of Erythropoietin for Smarter Protein Therapeutics: Structure–Function Relationships and Molecular Geometry | |
| EA043690B1 (ru) | Иммуномодулирующие слитые белки | |
| EA045432B1 (ru) | Иммуномодулирующие слитые белки |